Tysabri and PML: A Checklist for Informed Care Discussions

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. The medical community has long recognized that balancing therapeutic benefits with potential adverse effects requires clear communication. This page provides a practical checklist of discussion points to help you talk with your healthcare provider about PML monitoring, symptoms, and risk factors.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. Clinical presentation and diagnosis of PML involve a range of neurological symptoms that can include progressive weakness, visual disturbances, cognitive decline, and coordination difficulties. Diagnosis is typically confirmed through brain imaging, detection of JCV DNA in cerebrospinal fluid, and, when necessary, brain biopsy. In a large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024, 82.4% had a definite diagnosis and 17.6% had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). This study highlights the evolving clinical and laboratory characteristics of PML, which can complicate timely recognition.

Mechanism of PML Development and Risk Factors

The mechanistic pathway linking Tysabri to PML is rooted in its pharmacology. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. While this action reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance in the brain. This allows JCV, a virus that is latent in many individuals, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Regulatory Oversight

The adequacy of warnings regarding Tysabri and PML is a central issue in risk assessment. The boxed warning explicitly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to mitigate risk through mandatory patient and prescriber education and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude and nature of the PML risk, particularly in relation to individual risk factors.

Legal Considerations for Affected Patients

Settlement-related considerations for affected patients involve the timeline between Tysabri exposure and documented harm. PML can develop months to years after starting Tysabri, with risk increasing with longer treatment duration. The latency period between JCV reactivation and clinical symptoms can vary, and early symptoms may be subtle or nonspecific. This can delay diagnosis and treatment, potentially worsening outcomes. For patients who develop PML, the consequences are often devastating, with most cases resulting in death or severe, permanent disability. Legal claims may focus on whether the manufacturer provided sufficient warnings about PML risk, whether risk factors were adequately communicated, and whether monitoring protocols were followed. In summary, Tysabri is associated with a significant risk of PML, a life-threatening brain infection. The FDA has mandated strong warnings and a restricted distribution program to manage this risk. However, affected patients and their families may face complex medical and legal challenges, including questions about the adequacy of risk communication and the timing of diagnosis and intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, treatment duration longer than two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for Pennsylvania patients who developed PML from Tysabri?

Patients may pursue claims regarding inadequate warnings about PML risk, failure to communicate risk factors, or lapses in monitoring. Legal consultation is recommended to evaluate individual circumstances.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.